Healthcare has never been better at finding what might be wrong. Advances in AI, imaging, genomics, biomarkers, wearables, and increasingly sophisticated screening tools are enabling organizations to detect disease and identify risk earlier than ever before.
But earlier detection does not always mean better outcomes. As diagnostic technologies become more sensitive, healthcare is also finding more abnormalities, risk signals, and incidental findings - including those that may never have caused harm. This creates a new challenge: knowing when finding more is genuinely valuable and when it leads to unnecessary testing, treatment, anxiety, and cost.
At the same time, identifying a patient earlier is only the beginning. Healthcare systems need clear pathways for follow-up, specialist access, treatment, and reimbursement if earlier detection is going to translate into meaningful intervention rather than simply creating another point of friction in the patient journey.
This roundtable brings together leaders across diagnostics, pharma, precision medicine, medtech, genomics, payers, and digital health to explore the evolving value of earlier detection. The discussion will examine where advances in diagnostics are genuinely improving outcomes, how organizations should respond to increasingly sensitive health signals, and whether healthcare is prepared for everything new technologies are enabling us to find.
Join us to discuss:
When does earlier detection meaningfully improve outcomes - and when can finding more create unintended harm?
How should healthcare approach incidental findings and risk signals when their clinical significance is uncertain?
What needs to happen after a patient is identified as high risk for earlier detection to translate into earlier intervention?
How should evidence, reimbursement, and care pathways evolve as diagnostic technologies become increasingly predictive and sensitive?
